作者
Juergen Prattes, Joost Wauters, Daniele Roberto Giacobbe, Jon Salmanton-García, Johan Maertens, Marc Bourgeois, Marijke Reynders, Lynn Rutsaert, Niels Van Regenmortel, Piet Lormans, Simon Feys, Alexander Christian Reisinger, Oliver A Cornely, Tobias Lahmer, Maricela Valerio, Laurence Delhaes, Kauser Jabeen, Joerg Steinmann, Mathilde Chamula, Matteo Bassetti, Stefan Hatzl, Riina Rautemaa-Richardson, Philipp Koehler, Katrien Lagrou, Martin Hoenigl, Yves Debaveye, Marisa H Miceli, Jean-Jacques Tudesq, Gregor Paul, Robert Krause, Marina Linhofer, Jonas Frost, Peter Zechner, Matthias Kochanek, Philipp Eller, Jeffrey D Jenks, Sara Volpi, Anne-Pauline Bellanger, P Lewis White, Gustavo H Goldman, Paul Bowyer, Antonis Rokas, Sara Gago, Paolo Pelosi, Chiara Robba, Jean-Pierre Gangneux, Cornelia Lass-Floerl, Marina Machado, Patricia Muñoz
发表日期
2022/4/1
期刊
Clinical Microbiology and Infection
卷号
28
期号
4
页码范围
580-587
出版商
Elsevier
简介
Objectives
Coronavirus disease 2019 (COVID-19) -associated pulmonary aspergillosis (CAPA) has emerged as a complication in critically ill COVID-19 patients. The objectives of this multinational study were to determine the prevalence of CAPA in patients with COVID-19 in intensive care units (ICU) and to investigate risk factors for CAPA as well as outcome.
Methods
The European Confederation of Medical Mycology (ECMM) conducted a multinational study including 20 centres from nine countries to assess epidemiology, risk factors and outcome of CAPA. CAPA was defined according to the 2020 ECMM/ISHAM consensus definitions.
Results
A total of 592 patients were included in this study, including 11 (1.9%) patients with histologically proven CAPA, 80 (13.5%) with probable CAPA, 18 (3%) with possible CAPA and 483 (81.6%) without CAPA. CAPA was diagnosed a median of 8 days (range 0–31 days) after …
学术搜索中的文章
J Prattes, J Wauters, DR Giacobbe… - Clinical Microbiology and Infection, 2022
